H.C. Wainwright Rates Zymeworks a Buy on Promising ZW191 Cancer Drug Data

H.C. Wainwright sets $26 price target for Zymeworks after Phase 1 data shows ZW191 cancer drug outperforms FDA-approved competitor with 44% response rate.